Skip to main content
PMC home page
OncoTargets and Therapy logoLink to OncoTargets and Therapy
. 2015 Jun 12;8:1443–1449. doi: 10.2147/OTT.S84467

CpG oligodeoxyribonucleotide 7909 enhances radiosensitivity via downregulating Oct-4 expression in radioresistant lung cancer cells

Na Xing 1, Tiankui Qiao 1,✉, Xibing Zhuang 1, Sujuan Yuan 1, Qi Zhang 1, Guoxiong Xu 2
PMCID: PMC4472028  PMID: 26109868

Abstract

Radiotherapy is a powerful cure for local advanced non-small cell lung cancer. However, radioresistance and tumor relapse still occur in a high proportion of patients. Octamer-4 (Oct-4), a transcription factor of the POU family, plays a key role in maintaining chemoradioresistant properties and regulating cancer progression. In this study, we demonstrated that Oct-4 expression was significantly increased in radioresistant H460 (H460R) cell line. CpG oligodeoxyribonucleotide (CpG-ODN) 7909 sensitized H460R cells when combined with irradiation treatment. The clonogenic capacity was significantly decreased, and the values of D0 and Dq were lower than those of irradiation alone group. The sensitive enhancement ratio (SER) of D0 was 1.224. This combined treatment led to a dramatic reduction in Oct-4 expression in a dose-dependent manner and also showed increased percentage of cells in the radiosensitive G2/M phase relative to either treatment alone. These results identified that Oct-4 was involved in radioresistance. CpG-ODN 7909 could enhance radiosensitivity partly through downregulating Oct-4 expression in radioresistant lung cancer cells.

Keywords: CpG-ODN, Oct-4, lung cancer, TLR9, radiosensitivity

Introduction

Lung cancer remains lethal with 5-year survival rate generally lower than 20%, despite intensive therapeutic efforts.1 As a powerful cure for local advanced non-small cell lung cancer (NSCLC), radiotherapy remains largely palliative like most other antitumor therapies due to the adaptive resistance.2

Octamer-4 (Oct-4), a transcription factor of the POU family, plays a key role in the maintenance of embryonic stem cell proliferation and pluripotency.3,4 Moreover, Oct-4 is also overexpressed in some solid tumors, including breast, bladder, colorectal, renal, and lung cancers, which is associated with the maintenance of cancer stem-like and chemoradioresistant properties.5–12 The ectopic expression of Oct-4 controls epithelial–mesenchymal transition and plays an important role in enhancing malignancy and regulating cancer progression.5,8,9,13–15

Toll-like receptor 9 (TLR9) has been identified to be the receptor conferring CpG reactivity by directly engaging bacterial DNA or synthetic CpG oligodeoxyribonucleotides (CpG-ODNs) in a CpG motif-dependent manner.16–20 Owing to the immunostimulatory effects, CpG-ODNs targeting TLR9 have been considered as antitumor drugs, as monotherapy or in combination with radiotherapy, chemotherapy, or novel biological treatment.21 In previous studies, we demonstrated that CpG-ODNs present radiation-enhancing effects when combined with radiotherapy, which predominantly attributes to the release of cytokines, activation of natural killer cells, and induction of T-cell responses.22–24 Because of the overexpression of TLR9 in radiation-resistant human lung adenocarcinoma cell line, CpG-ODNs could even present significant radiosensitizing effects in radioresistant cells in vitro.25 However, whether CpG-ODNs affect the cancer stem-like properties of radioresistant lung cancer cells has yet to be elucidated. Accordingly, in the present study, we focus on the effects of CpG-ODNs on Oct-4 expression in radiation-resistant lung cancer cell line.

Materials and methods

Cell culture

The human NCI-H460 NSCLC cell line was purchased from Chinese Academy of Sciences (Shanghai, People’s Republic of China) and was cultured in RPMI-1640 medium (HyClone, MA,USA) supplemented with 10% fetal bovine serum at 37°C in a humidified atmosphere of 5% CO2.

Reagents

CpG-ODN 7909 (5′-TCGTCGTTTTGTCGTTTTGT CGTT-3′-) was selected according to the published reports and purchased from Shanghai Sangon Biological Engineering Technology & Services Co., Ltd. (Shanghai, People’s Republic of China).23,25,26 Chloroquine (CQ), a TLR9 inhibitor, was obtained from Sigma-Aldrich Co. (St Louis, MO, USA). CpG-ODN 7909 and CQ were separately resuspended in phosphate buffer saline to 1 mg/mL stock solutions and maintained at −20°C until use.

Generation of radioresistant cell line

H460 cells in an exponentially growing phase were irradiated at a dose of 6.37 Gy using a high-energy 6 MV X-ray accelerator delivering 2 Gy/min (source-to-surface distance =100 cm). For the generation of radioresistant variant cell line, cells were treated for ten rounds, and this radioresistant cell line was designated as radioresistant H460 (H460R).25

Study design

H460R cells were divided into six groups and plated in six-well plates (1.5×105/well): control group, CpG-ODN 7909 group (CpG group), irradiated group (IR group), irradiated + CpG-ODN 7909 group (IR + CpG group), irradiated + CpG-ODN 7909 + CQ group (IR + CpG + CQ group), and irradiated + CQ group (IR + CQ group). CpG-ODN 7909 was administrated to a final concentration of 20 µg/mL for 24 hours. CQ was used at a final concentration of 10 µg/mL in pretreatment during 1 hour prior to stimulation with CpG-ODN 7909. Then, cells were irradiated with 10 Gy. Logarithmic growing cells of each group were harvested at 48 hours after irradiation (IR).

Clonogenic survival assay

Cells that received different treatments were irradiated with graded IR doses ranging from 0 Gy to 8 Gy and then immediately trypsinized and seeded in triplicate in six-well plates (500–3,000 cells per well depending on the expected surviving fraction after IR27). After 10 days of incubation, cells were fixed and stained with crystal violet, and colonies ≥50 cells were counted. Clonogenic survival fraction was calculated as (irradiated cell colony numbers/unirradiated cell colony numbers) ×100%. Data were analyzed with linear quadratic and single-hit multitarget models.

Western blot analysis

Western blot analysis was used to determine the expression of Oct-4. The whole cell lysate was prepared using the sodium dodecyl sulfate (SDS) lysis buffer (Beyotime, Nantong, People’s Republic of China) with 1 mM phenylmethanesulfonyl fluoride (Beyotime). Protein concentration was determined using Coomassie blue fast staining solution (Beyotime). Protein extracts were separated by 10% SDS-polyacrylamide gel electrophoresis, transferred to PVDF membranes (EMD Millipore, Billerica, MA, USA), blocked with 5% nonfat dry milk in tris-buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) for 2 hours at room temperature, and then incubated with the following primary antibodies at 4°C overnight: anti-Oct-4 (Abcam, Cambridge, UK) and anti-β-actin (Santa Cruz, Dallas, TX, USA). Membranes were washed with TBS-T three times and probed with secondary antibodies for 1 hour at room temperature. Protein bands were visualized using chemiluminescence HRP substrate (EMD Millipore).

Cell cycle assay

The cell cycle was analyzed by measuring the DNA content stained with propidium iodide in the presence of RNase (BD Biosciences, San Jose, CA, USA) per manufacturer’s instructions. The cells were harvested and fixed with 75% ethanol at 4°C overnight and then incubated with 500 µL propidium iodide/RNase staining buffer (BD Biosciences) at room temperature for 15 minutes. The percentage of cells at each cell cycle was evaluated by a flow cytometer.

Statistical analysis

SPSS 21.0 and GraphPad Prism 5.0 were used for data analysis, and the results were presented as mean ± standard deviation. A P-value <0.05 was considered statistically significant difference.

Results

Generation of radioresistant lung cancer cells

The responses to IR between resistant cells and parental cells were analyzed by clonogenic assay. As shown in Figure 1 and Table 1, in the resistant H460R cells, a marked increase in D0 and N values and a broader initial shoulder were observed as compared to parental H460 cells. H460R cells were more resistant to cell death post-IR at each dose tested. These results indicated the acquired radioresistant characteristics of H460R cells.

Figure 1.

Figure 1

Open in a new tab

Analysis of radiosensitivity via clonogenic assay.

Notes: A single-hit multitarget model was used to draw dose–survival curves. The dose–survival curve of H460R cells exhibited a broader initial shoulder (indicating increase in Dq) and a smaller slope rate (indicating increase in D0). H460R cells were more resistant to cell death post-IR at each dose tested. *P<0.05 vs H460 cells at each dose tested.

Abbreviations: H460R, radioresistant H460; IR, irradiation.

Table 1.

Comparison of radiosensitivity between H460 cells and H460R cells

Cell line D0 Dq N
H460 1.299 1.056 2.254
H460R 1.569 2.481 4.862
Open in a new tab

Notes: The D0, Dq, and N values were significantly increased relative to parental H460 cells, which indicated the acquired radioresistant characteristics of H460R cells.

Abbreviation: H460R, radioresistant H460.

Elevated expression of Oct-4 in radioresistant lung cancer cells

Since Oct-4 expression plays an important role in regulating cancer progression and maintaining chemoradioresistant properties, we detected the level of Oct-4 in H460 and H460R cells. As shown in Figure 2, a substantial increase in Oct-4 expression was detected in H460R cells as compared to parental H460 cells, suggesting that Oct-4 was involved in radioresistance, and therefore, the radioresistant lung cancer cells may present more aggressive phenotypes than parental cells.

Figure 2.

Figure 2

Open in a new tab

The expression level of Oct-4 was higher in H460R cells compared with H460 cells.

Notes: Illustrative Western blots (A) and densitometric analysis (B) demonstrated that Oct-4 expression was significantly increased in H460R cells relative to parental H460 cells, indicating that Oct-4 was involved in radioresistance. *P<0.05 vs H460 cells.

Abbreviations: Oct-4, octamer-4; H460R, radioresistant H460.

Effects of CpG-ODN 7909 on expression of Oct-4 post-IR in radioresistant lung cancer cells

To determine whether CpG-ODN 7909 influences the expression of Oct-4, we treated H460R cells with an increasing concentration of CpG-ODN 7909 for 24 hours, exposed them to 10 Gy IR, and then incubated them for 48 hours. We then detected that, when combined with IR, CpG-ODN 7909 downregulated Oct-4 expression in H460R cells in a dose-dependent manner. Pretreatment of H460R cells with CQ caused a blockade in this reduction (Figure 3). These results indicated that CpG-ODN 7909 could reduce the Oct-4 expression through TLR9 signaling and may further influence the radiosensitivity of radioresistant lung cancer cells.

Figure 3.

Figure 3

Open in a new tab

CpG-ODN 7909 downregulated Oct-4 expression in H460R cells when combined with IR.

Notes: Illustrative Western blots and densitometric analysis demonstrated that CpG-ODN 7909 downregulated Oct-4 expression in H460R cells in a dose-dependent manner. This reduction could be blocked by the co-treatment of CQ. *P<0.05 vs 0 µg/mL; (a) P<0.05 vs IR group; (b) P<0.05 vs control group; and (c) P<0.05 vs CpG group.

Abbreviations: CpG-ODN 7909, CpG oligodeoxyribonucleotide 7909; Oct-4, octamer-4; H460R, radioresistant H460; IR, irradiation; CQ, chloroquine; IR group, irradiated group.

Effects of CpG-ODN 7909 on the radiosensitivity of radioresistant lung cancer cells

To assess and characterize the radiation-enhancing effects of CpG-ODN 7909, clonogenic survival analysis was performed. As shown in Figure 4 and Table 2, CpG-ODN 7909 presented significant radiation-enhancing effects. H460R cells treated with CpG-ODN 7909 plus IR exhibited decreased clonogenic capacity and displayed lower values of D0, Dq, and N than those of IR alone group, and the sensitive enhancement ratio (SER) of D0 was1.224. However, after the activation of TLR9 was blocked by CQ, we were unable to detect any radiation-enhancing effects.

Figure 4.

Figure 4

Open in a new tab

CpG-ODN 7909 presented significant radiation-enhancing effects on H460R cells.

Notes: Combined treatment with IR and CpG-ODN 7909 contributed to further reduction in the survival fractions at each dose tested compared to IR alone (*P<0.05 vs IR group at each dose tested). The dose–survival curve of H460R cells treated with CpG-ODN 7909 plus IR exhibited a narrow shoulder (indicating decrease in Dq) and a greater slope rate (indicating decrease in D0), indicating that CpG-ODN 7909 enhanced radiosensitivity when combined with IR treatment. However, the radiation-enhancing effects disappeared after TLR9 activation was blocked by CQ.

Abbreviations: CpG-ODN 7909, CpG oligodeoxyribonucleotide 7909; H460R, radioresistant H460; IR, irradiation; TLR9, toll-like receptor 9; CQ, chloroquine.

Table 2.

Comparison of radiosensitivity of H460R cells treated with IR, CpG-ODN 7909, or CQ

Group D0 Dq N SER
IR 1.569 2.481 4.862 –
IR + CpG 1.282 1.765 3.961 1.224
IR + CpG + CQ 1.515 2.132 4.086 1.036
IR + CQ 1.519 2.614 5.590 1.033
Open in a new tab

Notes: The D0, Dq, and N values of H460R cells treated with CpG-ODN 7909 plus IR were much lower relative to H460R cells irradiated alone, indicating the radiosensitization effect of CpG-ODN 7909 plus IR on H460R cells. The SER of D0 was 1.224. However, the radiation-enhancing effects disappeared after TLR9 activation was inhibited by CQ.

Abbreviations: H460R, radioresistant H460; IR, irradiation; CpG-ODN 7909, CpG oligodeoxyribonucleotide 7909; CQ, chloroquine; SER, sensitive enhancement ratio; TLR9, toll-like receptor 9.

Effects of CpG-ODN 7909 on cell cycle regulation after IR in radioresistant lung cancer cells

To determine if radiosensitizing effects of CpG-ODN 7909 were related to cell cycle regulation, we performed flow cytometric analysis to determine the number of cells in each cell cycle phase. As shown in Figure 5A and B, combined treatment with IR and CpG-ODN 7909 showed an increased percentage of cells in G2/M phase compared to either treatment alone in H460R cells, which could be blocked by the co-treatment of CQ. The results above suggested that CpG-ODN 7909 allowed H460R cells to produce G2/M arrest through TLR9 signaling.

Figure 5.

Figure 5

Open in a new tab

Effect of CpG-ODN 7909 on G2/M phase arrest in H460R cells.

Notes: (A) Flow cytometric analysis of cell cycle distribution. (B) The proportion of cells in the G2/M phase. CpG-ODN 7909 or IR could increase the proportion of cells in the G2/M phase. However, combined treatment showed a much higher percentage in the G2/M phase compared to either treatment alone. This reinforcing effect could be blocked by the co-treatment of CQ, suggesting that CpG-ODN 7909 could prolong cell-cycle arrest in the G2/M phase and enhance radiosensitivity through TLR9 signaling. (a) P<0.05 vs IR group; (b) P<0.05 vs control group; and (c) P<0.05 vs CpG group.

Abbreviations: CpG-ODN 7909, CpG oligodeoxyribonucleotide 7909; H460R, radioresistant H460; IR, irradiation; CQ, chloroquine; TLR9, toll-like receptor 9.

Discussion

Lung cancer is the most common diagnosed tumor with a poor prognosis.1 Although radiotherapy has been a powerful cure for locally advanced NSCLC, its efficiency remains limited as tumors develop adaptive response to radiotherapy and become more aggressive, resistant, and invasive.2 As a positive regulator of tumor dedifferentiation, Oct-4 plays an important role in maintaining the cancer stem-like and chemoradioresistant properties.10,12 In the present study, we found that the resistant H460R cells showed a significant increase in Oct-4 expression relative to parental cells, which indicated that Oct-4 was associated with the radioresistant phenotype. Thus, targeting Oct-4 might be an effective approach to interfere with the properties of cancer stem-like cells (CSCs) and improve the efficacy of cancer treatments.

Due to the immune stimulatory effects, CpG-ODNs have been widely used in cancer therapy, eg, treating oral squamous cell carcinoma, brain tumor, breast cancer, and lung cancer.28–31 In our previous studies, we have demonstrated that CpG-ODNs could enhance apoptosis, induce prolonged G2/M arrest, and stimulate TNF-α secretion in human NSCLC cells and thereby enhanced radiosensitivity. As TLR9 was overexpressed in radiation-resistant NSCLC cells, CpG-ODNs could even present significant radiosensitizing effects in radioresistant cells in vitro.23,25 All these results urged us to further explore the sensitization mechanism of CpG-ODNs and the influence of CpG-ODNs on Oct-4, as Oct-4 is associated with the radioresistant phenotype.

The ectopic expression of Oct-4 controls epithelial–mesenchymal transition and plays an important role in regulating cancer progression and maintaining the chemoradioresistant properties.5,8,9,13–15 In this study, overexpression of Oct-4 was observed in H460R cells. However, CpG-ODNs induced a dramatic reduction in Oct-4 expression in a dose-dependent manner when combined with IR.

TLR9-CpG-DNA interaction is pH dependent and occurs at the acidic pH (6.5–4.5) found in endosomes and lysosomes. CQ, a known TLR9 antagonist, is a weak base that can partition into endosomes and perturb endosomal pH.32,33 CQ has been widely used as the inhibitor for endosomal acidification to inhibit the activation of TLR9.34–37 In the present study, pretreatment of H460R cells with CQ caused a blockade in the reduction of Oct-4 expression induced by CpG-ODNs, suggesting that CpG-ODNs could reduce the Oct-4 expression through TLR9 signaling and may therefore present radiosensitizing effects. Cell cycle phase determines cells’ relative radiosensitivity, with cells being most sensitive in the G2/M phase.38 As shown above, combined treatment with IR and CpG-ODNs led to the accumulation of cells in the G2/M phase. Once the activation of TLR9 was blocked by CQ, the CpG-ODN-induced G2/M arrest was abrogated. These results further demonstrated that CpG-ODNs sensitized H460R cells when combined with radiotherapy through TLR9 signaling. As shown in Table 2, the SER of D0 was about 1.224.

In summary, Oct-4 was involved in radioresistance. Combined treatment with CpG-ODNs and IR presented significant radiosensitizing effects partly through downregulating Oct-4 expression. As cancer stem-like cells phenotype is a dynamic process and can be acquired through Oct-4-mediated dedifferentiation,7,11,12 further investigation remains to be performed to study the role of Oct-4 and the related signaling pathway in radioresistance and to explore the direct effect of CpG-ODNs on CSCs.

Acknowledgments

This work was supported by the Scientific Fund of the Shanghai Municipal Health Bureau.

Footnotes

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.Allemani C, Weir HK, Carreira H, et al. CONCORD Working Group Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2) Lancet. 2014;385(9972):977–1010. doi: 10.1016/S0140-6736(14)62038-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005;5(7):516–525. doi: 10.1038/nrc1650. [DOI] [PubMed] [Google Scholar]
  • 3.Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 2000;24(4):372–376. doi: 10.1038/74199. [DOI] [PubMed] [Google Scholar]
  • 4.Babaie Y, Herwig R, Greber B, et al. Analysis of Oct4-dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. Stem Cells. 2007;25(2):500–510. doi: 10.1634/stemcells.2006-0426. [DOI] [PubMed] [Google Scholar]
  • 5.Liu CG, Lu Y, Wang BB, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg. 2011;253(6):1165–1171. doi: 10.1097/SLA.0b013e318214c54e. [DOI] [PubMed] [Google Scholar]
  • 6.Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer. 2007;120(7):1598–1602. doi: 10.1002/ijc.22508. [DOI] [PubMed] [Google Scholar]
  • 7.Wen K, Fu Z, Wu X, Feng J, Chen W, Qian J. Oct-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: effects associated with STAT3/Survivin. Cancer Lett. 2013;333(1):56–65. doi: 10.1016/j.canlet.2013.01.009. [DOI] [PubMed] [Google Scholar]
  • 8.Kim K, Ro JY, Kim S, Cho YM. Expression of stem-cell markers OCT-4 and CD133: important prognostic factors in papillary renal cell carcinoma. Hum Pathol. 2012;43(12):2109–2116. doi: 10.1016/j.humpath.2012.05.006. [DOI] [PubMed] [Google Scholar]
  • 9.Chen Z, Wang T, Cai L, et al. Clinicopathological significance of non-small cell lung cancer with high prevalence of Oct-4 tumor cells. J Exp Clin Cancer Res. 2012;31:10. doi: 10.1186/1756-9966-31-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Chen YC, Hsu HS, Chen YW, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One. 2008;3(7):e2637. doi: 10.1371/journal.pone.0002637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hu T, Liu S, Breiter DR, Wang F, Tang Y, Sun S. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res. 2008;68(16):6533–6540. doi: 10.1158/0008-5472.CAN-07-6642. [DOI] [PubMed] [Google Scholar]
  • 12.Kumar SM, Liu S, Lu H, et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene. 2012;31(47):4898–4911. doi: 10.1038/onc.2011.656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wang D, Lu P, Zhang H, et al. Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget. 2014;5(21):10803–10815. doi: 10.18632/oncotarget.2506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Chiou SH, Wang ML, Chou YT, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010;70(24):10433–10444. doi: 10.1158/0008-5472.CAN-10-2638. [DOI] [PubMed] [Google Scholar]
  • 15.Huang P, Chen J, Wang L, et al. Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence. Med Oncol. 2012;29(2):829–834. doi: 10.1007/s12032-011-9962-4. [DOI] [PubMed] [Google Scholar]
  • 16.Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009;61(3):195–204. doi: 10.1016/j.addr.2008.12.008. [DOI] [PubMed] [Google Scholar]
  • 17.Hemmi H, Takeuchi O, Kawai T, et al. A toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740–745. doi: 10.1038/35047123. [DOI] [PubMed] [Google Scholar]
  • 18.Bauer S, Kirschning CJ, Häcker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A. 2001;98(16):9237–9242. doi: 10.1073/pnas.161293498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Cornélie S, Hoebeke J, Schacht AM, et al. Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition. J Biol Chem. 2004;279(15):15124–15129. doi: 10.1074/jbc.M313406200. [DOI] [PubMed] [Google Scholar]
  • 20.Latz E, Schoenemeyer A, Visintin A, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004;5(2):190–198. doi: 10.1038/ni1028. [DOI] [PubMed] [Google Scholar]
  • 21.Holtick U, Scheulen ME, von Bergwelt-Baildon MS, Weihrauch MR. Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs. 2011;20(3):361–372. doi: 10.1517/13543784.2011.553187. [DOI] [PubMed] [Google Scholar]
  • 22.Li R, Song Y, Chen W. Enhancing radiosensitivity of human pulmonary adenocarcinoma cell line A549 by CpG ODN1826. Cancer Biother Radiopharm. 2011;26(1):69–76. doi: 10.1089/cbr.2010.0849. [DOI] [PubMed] [Google Scholar]
  • 23.Zha L, Qiao T, Yuan S, Lei L. Enhancement of radiosensitivity by CpG-oligodeoxyribonucleotide-7909 in human non-small cell lung cancer A549 cells. Cancer Biother Radiopharm. 2010;25(2):165–170. doi: 10.1089/cbr.2009.0686. [DOI] [PubMed] [Google Scholar]
  • 24.Yuan S, Qiao T, Chen W. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor. Cancer Biother Radiopharm. 2011;26(2):203–208. doi: 10.1089/cbr.2010.0871. [DOI] [PubMed] [Google Scholar]
  • 25.Yan L, Xu G, Qiao T, Chen W, Yuan S, Li X. CpG-ODN 7909 increases radiation sensitivity of radiation-resistant human lung adenocarcinoma cell line by overexpression of toll-like receptor 9. Cancer Biother Radiopharm. 2013;28(7):559–564. doi: 10.1089/cbr.2012.1450. [DOI] [PubMed] [Google Scholar]
  • 26.Witzig TE, Wiseman GA, Maurer MJ, et al. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am J Hematol. 2013;88(7):589–593. doi: 10.1002/ajh.23460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Short SC, Giampieri S, Worku M, et al. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells. Neuro Oncol. 2011;13(5):487–499. doi: 10.1093/neuonc/nor010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ruan M, Thorn K, Liu S, et al. The secretion of IL-6 by CpG-ODN-treated cancer cells promotes T-cell immune responses partly through the TLR-9/AP-1 pathway in oral squamous cell carcinoma. Int J Oncol. 2014;44(6):2103–2110. doi: 10.3892/ijo.2014.2356. [DOI] [PubMed] [Google Scholar]
  • 29.Jarry U, Donnou S, Vincent M, et al. Treg depletion followed by intracerebral CpG-ODN injection induce brain tumor rejection. J Neuroimmunol. 2014;267(1–2):35–42. doi: 10.1016/j.jneuroim.2013.12.005. [DOI] [PubMed] [Google Scholar]
  • 30.Xia Y, Gupta GK, Castano AP, Mroz P, Avci P, Hamblin MR. CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer. J Biophotonics. 2014;7(11–12):897–905. doi: 10.1002/jbio.201300072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Sorrentino R, Morello S, Forte G, et al. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am J Respir Crit Care Med. 2011;183(10):1369–1379. doi: 10.1164/rccm.201010-1738OC. [DOI] [PubMed] [Google Scholar]
  • 32.Mellman I, Fuchs R, Helenius A. Acidification of the endocytic and exocytic pathways. Annu Rev Biochem. 1986;55:663–700. doi: 10.1146/annurev.bi.55.070186.003311. [DOI] [PubMed] [Google Scholar]
  • 33.Rutz M, Metzger J, Gellert T, et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol. 2004;34(9):2541–2550. doi: 10.1002/eji.200425218. [DOI] [PubMed] [Google Scholar]
  • 34.Fiola S, Gosselin D, Takada K, Gosselin J. TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J Immunol. 2010;185(6):3620–3631. doi: 10.4049/jimmunol.0903736. [DOI] [PubMed] [Google Scholar]
  • 35.Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186(8):4794–4804. doi: 10.4049/jimmunol.1000702. [DOI] [PubMed] [Google Scholar]
  • 36.Tillack K, Breiden P, Martin R, Sospedra M. T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J Immunol. 2012;188(7):3150–3159. doi: 10.4049/jimmunol.1103414. [DOI] [PubMed] [Google Scholar]
  • 37.Sanjuan MA, Rao N, Lai KT, et al. CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J Cell Biol. 2006;172(7):1057–1068. doi: 10.1083/jcb.200508058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(4):928–942. doi: 10.1016/j.ijrobp.2004.03.005. [DOI] [PubMed] [Google Scholar]

Articles from OncoTargets and therapy are provided here courtesy of Dove Press

RESOURCES